Determination of MIC and Disk Diffusion Quality Control Guidelines for Meropenem–Vaborbactam, a Novel Carbapenem/Boronic Acid β-Lactamase Inhibitor Combination

Authors

Erik Munson, Marquette UniversityFollow
Michael D. Huband, JMI Laboratories
Mariana Castanheira, JMI Laboratories
Kelley A. Fedler, JMI Laboratories
Robert K. Flamm, JMI Laboratories

Document Type

Article

Language

eng

Publication Date

4-2018

Publisher

Elsevier

Source Publication

Diagnostic Microbiology and Infectious Disease

Source ISSN

0732-8893

Abstract

Meropenem–vaborbactam is a carbapenem/cyclic boronic acid β-lactamase inhibitor combination primarily active against Gram-negative bacilli, including those harboring class A serine carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC). A Clinical and Laboratory Standards Institute M23-A4 (Tier 2) quality control study established broth microdilution and disk diffusion ranges for reference strains. Two KPC-producing K. pneumoniae ATCC strains are recommended for quality control testing.

Comments

Accepted version. Diagnostic Microbiology and Infectious Disease, Vol. 90, No. 4 (April 2018): 324-328. DOI. © 2018 Elsevier B.V. Used with permission.

Recommended Citation

Munson, Erik; Huband, Michael D.; Castanheira, Mariana; Fedler, Kelley A.; and Flamm, Robert K., "Determination of MIC and Disk Diffusion Quality Control Guidelines for Meropenem–Vaborbactam, a Novel Carbapenem/Boronic Acid β-Lactamase Inhibitor Combination" (2018). Clinical Lab Sciences Faculty Research and Publications. 38.
https://epublications.marquette.edu/clinical_lab_fac/38